Abstract A012: Investigating the heterogeneity of different KRAS point mutations on DRP1 activation and its regulation of the TME in pancreatic cancer
Despite research efforts, outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain dismal, with a 5-year survival rate of 13%. Our group identified that DRP1 loss in KRAS-mutant PDAC tumor cells alters mitochondrial shape and reduces glycolysis and cell proliferation in murine models. However, how Ra...